A method of treating COVID-19 in a subject, whereby the subject in need thereof is administered, via the oral mucosa, a bioefficient rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and a sugar alcohol, and (b) a therapeutically effective amount of cannabidiol (CBD) or a derivative/analog thereof.

The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with encephalocele. In a further embodiment the types of seizures include absence, focal seizures with secondary generalisation and focal seizures with impairment. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients diagnosed with a SPATA5 mutation. In a further embodiment the types of seizures include tonic, myoclonic and focal seizures with impairment. Preferably the dose of CBD is between mg/kg/day to 50 mg/kg/day.

A topical composition for treatment of a skin condition comprising a mixture of Leptospermum scoparium oil (manuka oil or β-triketones extracted from manuka oil), at least one of Cymbopogon martinii (palmarosa oil), CBD oil or isolate, or Pogostemon cablin (patchouli oil), and a carrier composition.

A method for treating endometrial cancer comprising: administering to a patient a cannabis extract (CE) wherein the cannabis extract comprises cannabidiol (CBD) at between 50% and 99% by weight of the CE.

A method for treating endometrial cancer comprising: administering to a patient a cannabis extract (CE) wherein the cannabis extract comprises cannabidiol (CBD) at between 50% and 99% by weight of the CE.

The frozen cannabis product may be included in a drink that also includes an ingestible liquid, such as soda, water, or juice. The frozen cannabis product is formed from a base constituent and at least one of tetrahydrocannabinol (THC) and cannabidiol (CBD) that are admixed together in liquid form and then frozen to make cannabis ice. The cannabis ice melts with a known amount of the THC and/or CBD, thereby allowing a user to refill their drink as many times as they want while using the same cannabis ice with minimal risk of an overdosing on the THC and/or CBD.

The invention provides synergistic topical formulations comprising a cannabinoid; an extract from Paeonia lactiflora; and optionally allantoin. The invention further provides uses of these formulations in treating certain inflammatory diseases, wounds, scarring and the like. Examples of such diseases or conditions are arthritis, such as rheumatoid arthritis. Other examples are skin diseases or conditions, such as wound and consequent scarring.

The invention relates to an oral cannabinoid formulation comprising: a cannabinoid component comprising a cannabinoid; a carrier in the form of a medium chain triglyceride (MCT); and a tocopheryl phosphate component comprising mono-(tocopheryl) phosphate (TP) and di-(tocopheryl) phosphate (T2P) wherein the mass ratio of the cannabinoid to the tocopheryl phosphate component is about 10:1 to 1:10.

The invention relates to an oral cannabinoid formulation comprising: a cannabinoid component comprising a cannabinoid; a carrier in the form of long chain triglyceride (LCT) or long chain fatty acid (LCFA); and a tocopheryl phosphate component comprising mono-(tocopheryl) phosphate (TP) and di-(tocopheryl) phosphate (T2P) wherein the mass ratio of the cannabinoid to the tocopheryl phosphate component is about 10:1 to 1:10.